Business Model Breakdown
How Tempus AI Inc Makes Money
TEM
Market Cap
$10.0B
Annual Revenue
$1.1B
Profit Margin
-19.3%
Employees
2,400
The Short Version
Tempus AI operates as an AI-driven precision medicine company that collects and analyzes vast amounts of clinical and molecular data to help physicians make personalized treatment decisions for cancer patients and to assist life science companies in drug discovery and development. It essentially provides 'intelligent' diagnostics and data insights that accelerate the understanding and treatment of disease, primarily in oncology.
Where the Revenue Comes From
Diagnostics (~75% of revenue, e.g., genomic sequencing, hereditary cancer testing, MRD tests)
Data & Applications (~25% of revenue, e.g., licensing its multi-modal data, AI-powered software solutions)
Who buys: Oncologists and other healthcare providers, hospitals and health systems, pharmaceutical companies, academic research institutions.
Why It Works (Competitive Advantages)
- ✔Proprietary multi-modal data library (genomic, clinical, imaging, etc.)
- ✔AI-driven diagnostic platform offering precision medicine insights
- ✔Strategic partnerships and robust oncology diagnostics portfolio
Economic Moat: Narrow (Intangible Assets/IP (proprietary AI algorithms, extensive data library), Switching Costs (integration into clinical workflows, data dependency), Network Effects (more data enhances insights, attracting more partners/data))
What Our Analysis Says
DVR Score as of May 6, 2026
Tempus AI Inc. continues to operate in the high-growth, AI-driven precision medicine sector with a vast TAM and a strong strategic vision, bolstered by its proprietary multi-modal data library and recent acquisitions like Ambry. Q1 2026 earnings showed a revenue beat and strong gross margin expansion (63.8%), with exceptional MRD volume growth (+500% YoY), affirming its market position. However, significant concerns have emerged since the last analysis: revenue growth decelerated from 83% to 36.1% YoY, net losses widened substantially to ($125.9M), and the company remains cash flow negative. Despite an improving adjusted EBITDA trend and raised FY2026 guidance for revenue and adjusted EBITDA, the market reacted negatively, and Zacks issued a 'Sell' rating. The current financial health, characterized by ongoing cash burn and a net debt position, alongside negative short-term sentiment, has tempered the immediate 10x growth probability, though long-term potential remains.